Flibanserin
Flibanserinflibanserin

98%+Purity Flibanserin Powder

Flibanserin ( Addyi) is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems.

Flibanserin Details:

 

Name: Flibanserin
Synonyms: Flibanserin;Bimt 17;Filbanserin;Flibanerins

3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one

CAS: 167933-07-5
MF: C20H21F3N4O
MW: 390.4
Molecular Structure:

CAS 167933-07-5 Sex Enhancement Drugs Flibanserin MF C20H21F3N4O 99% Assay
Appearance: White powder
Grade: Pharmaceutical grade
Usage: Adrug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD).

 

Flibanserin COA:

 

Items Specification
Appearance white crystals or crystalline powder, has a faint, characteristic odor and bitter taste
Solubility freely soluble in water and 95%ethanol, sparingly soluble in acetic anhydride and practically insoluble in diethyl ether
pH 3.5-4.5
Identification 1, red to dark purple color appears with(III)iron chloride
2, light red precipitate formed with reinecke salt TS
3, UV spectrum meet the reference
4, solution (1%) responds to the qualitative test for chloride
Melting point 139-143 celcius degree
Clarity and color of solution clear and colorless
Sulfate 0.048%max
Heavy metals 10ppm max
As 2ppm max
Organic acid(0.1M NaOH) 0.54ml max
Loss on drying 0.5% max
Residue on ignition 0.1%max
Residual organic Solvents (GC) Xylol 0.217%max
Isopropanol 0.5%max
Related substances(HPLC) Total impurity 1.5%max
Single impurity0.5%max
Free P-chloro phenoxy acetic 0.5%max
Count of bacteria bacillus 1000/1g max
Mildew 100/1g max
Microzyme 100/1g max
Assay(C12H16CINO3.HCl,on dry basis) 98%min

 

Flibanserin Description:

 

Flibanserin, a Medical Treatment for Female Hypoactive Sexual Desire Disorder.
Flibanserin ( Addyi) is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman’s sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.
Flibanserin, (or rumored trademark name Girosa or Ectris) created by Boehringer Ingelheim, a German Pharmaceutical company, was originally being created as an anti-depressant but after testing for such was found to be a poor treatment for depression. Similarly how Viagra was being experimented with originally to treat high blood pressure and angina (a heart condition). Interestingly while females where being questioned about their trial experiences for depression, a large number noticed an unexpected positive side effect from Flibanserin. They discovered that many woman where reporting more sexual interest and overall satisfying sexual experiences than before. Apparently some woman who where taking part in the trials didn’t want to stop the testing based on this fact alone. This led the company to clinically testing this new compound for this exact reason.


Flibanserin Application:

 

A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited

by others, but it’s hit a potentially serious snag. The drug didn’t boost women’s desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin. (The FDA usually follows the recommendations of its expert panels. ) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn’t “particularly compelling. ”
It’s called the “little pink pill, ” a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it’s approved, it would become the first drug of its kind on the market.

 

Your Name

Your Email

Inquiry Product

Your Message

Captcha